The hENT1 inhibitor, NBMPR, decreased sensitivity to GEM in bladder cancer cells and increased sensitivities to SZY-200 and CP-4126 (Figures 3B-D). This evidence concerns the gene SLC29A1 and urinary bladder cancer.